Oncology Business Management

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

OncLive and Tulane Cancer Center at the Tulane University School of Medicine have joined forces to promote awareness of new developments in cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced today.

The COA has weighed in on a new system of higher value performance for oncologists, saying it is a step in the right direction but needs to be supported by broader reforms.

OncLive today welcomes Rutgers Cancer Institute of New Jersey as a partner in promoting awareness of the most recent advances in cancer care through OncLive's Strategic Alliance Partnership program

The only therapeutic cancer vaccine ever to win approval from the FDA has repeatedly missed sales projections, plunging the company that developed it into bankruptcy proceedings.

The American Board of Internal Medicine (ABIM) is making substantial changes to its Maintenance of Certification Program (MOC) for internists and subspecialists.

OncLive® welcomes the University of Chicago Medicine Comprehensive Cancer Center as a partner in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program.

The FDA has expanded the approval of ibrutinib for the treatment of patients with Waldenström’s macroglobulinemia, according to a press release.

OncLive® and the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins Medicine have become collaborators to raise awareness of leading innovations in cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced.